Experienced in Progressive Osseous Heteroplasia

Dr. Daniel E. Spratt

Radiation Oncology
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 
Accepting New Patients
Offers Telehealth
Experienced in Progressive Osseous Heteroplasia
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Spratt is a Radiation Oncologist in Cleveland, Ohio. Dr. Spratt is rated as an Experienced provider by MediFind in the treatment of Progressive Osseous Heteroplasia. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bone Tumor, Prostatectomy, and Orchiectomy. Dr. Spratt is currently accepting new patients.

His clinical research consists of co-authoring 502 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in MI
Hospital Affiliations
Uh Cleveland Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UNIVERSITY HOSPITALS MEDICAL GROUP INC
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer
A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Niraparib, Leuprolide, Abiraterone acetate
Study Phase: Phase 1/Phase 2
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Radiation
Study Phase: Phase 1
A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer
A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer
Enrollment Status: Completed
Publish Date: November 27, 2019
Intervention Type: Procedure, Radiation
Study Phase: Phase 1
A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for the Treatment of Localized Renal Cell Carcinoma (RCC)
A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for the Treatment of Localized Renal Cell Carcinoma (RCC)
Enrollment Status: Terminated
Publish Date: November 07, 2017
Intervention Type: Radiation
Study Phase: Not Applicable
View 12 Less Clinical Trials

502 Total Publications

Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials.
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials.
Journal: JAMA network open
Published: August 20, 2025
Similar Doctors
Advanced in Progressive Osseous Heteroplasia
Dr. David B. Mansur
Radiation Oncology
Advanced in Progressive Osseous Heteroplasia
Dr. David B. Mansur
Radiation Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Mansur is a Radiation Oncologist in Cleveland, Ohio. Dr. Mansur is rated as a Distinguished provider by MediFind in the treatment of Progressive Osseous Heteroplasia. His top areas of expertise are Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Cutaneous T-Cell Lymphoma (CTCL), Metastatic Brain Tumor, and Gamma Knife Radiosurgery. Dr. Mansur is currently accepting new patients.

Experienced in Progressive Osseous Heteroplasia
Dr. Jennifer A. Dorth
Radiation Oncology
Experienced in Progressive Osseous Heteroplasia
Dr. Jennifer A. Dorth
Radiation Oncology

University Hospitals Medical Group Inc

3909 Orange Pl, Suite 1100, 
Beachwood, OH 
 (7.1 miles away)
216-896-1755
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jennifer Dorth is a Radiation Oncologist in Beachwood, Ohio. Dr. Dorth is rated as a Distinguished provider by MediFind in the treatment of Progressive Osseous Heteroplasia. Her top areas of expertise are Anal Cancer, Pancreatic Cancer, Prostate Cancer, Laryngeal Cancer, and Tissue Biopsy. Dr. Dorth is currently accepting new patients.

Experienced in Progressive Osseous Heteroplasia
Dr. Angela Y. Jia
Radiation Oncology
Experienced in Progressive Osseous Heteroplasia
Dr. Angela Y. Jia
Radiation Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (0.1 miles away)
216-844-3133
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Angela Jia is a Radiation Oncologist in Cleveland, Ohio. Dr. Jia is rated as an Advanced provider by MediFind in the treatment of Progressive Osseous Heteroplasia. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Anal Cancer, Progressive Osseous Heteroplasia, and Prostatectomy. Dr. Jia is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spratt's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile